Drugs / PD1-CD19-CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04213469 | Mar 2020 → Nov 2021 | B-cell non-Hodgkin lymphoma | Bioray Laboratories | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD1-CD19-CART | “PD1-CD19-CART in Patients With r/r B-cell Lymphoma” NCT04213469 ↗ |
| Action | Deplete | “an innovative type of anti-CD19 CAR-T cell with PD1 integration was developed and showed superior ability to eradicate tumour cells in xenograft models.” PMID 36045296 ↗ Aug 2022 |
| Modality | Cell therapy | “PD1-CD19-CART is a kind of chimeric antigen T cell” NCT04213469 ↗ |
| Route | Other | “A dose of PD1-CD19-CART will be infused on day 0.” NCT04213469 ↗ |